Discover the groundbreaking patent by Allogene Therapeutics for CD19-specific CARs resistant to rituximab binding. Learn about the innovative methods and features of these engineered immune cells.

Wall Street expects a year-over-year increase in earnings on lower revenues when Allogene Therapeutics (ALLO) reports results for the quarter ended March 2024. While this widely-known consensus ...

"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates ...

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops ...

JPM Securities Life Sciences Conference Tuesday, May 14, 20246:00am PT/9:00am ET Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...